Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 1175-1182

  Kajanne, Risto ^a,b   Miettinen, Päivi ^a,c   Tenhunen, Mikko ^b   Leppä, Sirpa ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

AKT; AP 1; EGF R; Growth; Prostate cancer; Radiation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUND;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVITY; GAMMA RADIATION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 70449553846     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000434     Document Type: Article

References (27)

1. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG and Hanks GE: Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol 171: 1132-1136, 2004. (Pubitemid 38327542)
2. Zelefsky MJ, Fuks Z, Hunt M, et al: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166: 876-881, 2001. (Pubitemid 32750970)
3. Di Lorenzo G, Tortora G, D'Armiento FP, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444, 2002. (Pubitemid 35340719)
4. Schlomm T, Kirstein P, Iwers L, et al: Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13: 6579-6584, 2007. (Pubitemid 350206791)
5. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
6. Sgambato A, Camerini A, Faraglia B, et al: Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 201: 97-105, 2004. (Pubitemid 39187048)
7. Sirotnak FM, She Y, Lee F, Chen J and Scher HI: Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 8: 3870-3876, 2002. (Pubitemid 35424782)
8. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A and Bologna M: Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 129: 165-174, 2003. (Pubitemid 36583697)
9. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE and Ellis LM: Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397-405, 2005. (Pubitemid 40075820)
10. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174, 2008.
11. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
12. Majumder PK and Sellers WR: Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474, 2005.
13. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291-4296, 1999. (Pubitemid 29418745)
14. Gottschalk AR, Doan A, Nakamura JL, Stokoe D and Haas- Kogan DA: Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 63: 1221-1227, 2005. (Pubitemid 41505303)
15. Angel P and Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991.
16. Whitmarsh AJ and Davis RJ: Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74: 589-607, 1996.
17. Cao H, Dronadula N and Rao GN: Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. Am J Physiol Cell Physiol 290: C172-C182, 2006.
18. Tiwari G, Sakaue H, Pollack JR and Roth RA: Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene. Mol Cancer Res 1: 475-484, 2003. (Pubitemid 36459258)
19. Ouyang X, Jessen WJ, Al-Ahmadie H, et al: Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 68: 2132-2144, 2008.
20. Kajanne R, Miettinen P, Mehlem A, et al: EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 212: 489-497, 2007. (Pubitemid 47025639)
21. Eriksson M and Leppa S: Mitogen-activated protein kinases and activator protein 1 are required for proliferation and cardiomyocyte differentiation of P19 embryonal carcinoma cells. J Biol Chem 277: 15992-16001, 2002. (Pubitemid 34967882)
22. Brunn GJ, Hudson CC, Sekulic A, et al: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277: 99-101, 1997. (Pubitemid 27450655)
23. Schreiber M, Kolbus A, Piu F, et al: Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13: 607-619, 1999. (Pubitemid 29131884)
24. Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11-31, 2001. (Pubitemid 32520251)
25. Stein RC: Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8: 237-248, 2001. (Pubitemid 32947646)
26. Belguise K, Kersual N, Galtier F and Chalbos D: FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24: 1434-1444, 2005. (Pubitemid 40343123)
27. Casalino L, Bakiri L, Talotta F, et al: Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J 26: 1878-1890, 2007.